Hepatitis B Clinical Trial
Official title:
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children
Verified date | January 2020 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current trial will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A
vaccine when administered as a booster dose following priming in the first year of life with
the same vaccine.
This protocol posting deals with objectives & outcome measures of the booster phase. The
objectives & outcome measures of the primary phase are presented in a separate protocol
posting (NCT number = NCT00970307).
Status | Completed |
Enrollment | 391 |
Est. completion date | December 3, 2010 |
Est. primary completion date | December 3, 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 18 Months |
Eligibility |
Inclusion Criteria: - Subjects who the investigator believes that parent(s)/ legally acceptable representative(s) can and will comply with the requirements of the protocol. - Subjects who have completed the full three-dose primary vaccination course according to their group allocation in the primary study DTPa-HBV-IPV=Hib-MenC-TT-002 (112157). - A male or female between, and including, 12 and 18 months of age at the time of booster vaccination. - Written informed consent obtained from the parent(s)/ legally acceptable representative(s) of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: - Child in care. - Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the dose of study vaccine, or planned use during the study period. - Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination. - Planned administration/administration of immunoglobulins and/or any blood products within three months before the booster dose, or during the study period. - Planned administration/administration of any vaccine not foreseen by the study protocol during the period starting 30 days before and ending 30 days after the booster dose. - Participation in another clinical study since the primary study DTPa-HBV-IPV/Hib-MenC-TT-002 in which the subject has been or will be exposed to an investigational or a non-investigational product. - Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib, pneumococcal and MenC vaccination or disease since the conclusion visit of study DTPa-HBV-IPV/Hib-MenC-TT-002. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. - History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. - The following adverse event having occurred after previous administration of DTP vaccine: - Encephalopathy. - Temperature of >= 40.5°C (rectal temperature) within 48 hours of vaccination, not due to another identifiable cause. - Collapse or shock-like state within 48 hours of vaccination. - Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting >= 3 hours. - Seizures with or without fever occurring within 3 days of vaccination. The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met: • Acute disease and/or fever at the time of enrolment. - Fever is defined as temperature = 37.5°C on oral, axillary or tympanic setting, or = 38.0°C on rectal setting. - Subjects with a minor illness without fever may be enrolled at the discretion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Poland | GSK Investigational Site | Bydgoszcz | |
Poland | GSK Investigational Site | Debica | |
Poland | GSK Investigational Site | Krakow | |
Poland | GSK Investigational Site | Krakow | |
Poland | GSK Investigational Site | Siemianowice Slaskie | |
Poland | GSK Investigational Site | Tarnow | |
Poland | GSK Investigational Site | Torun | |
Poland | GSK Investigational Site | Trzebnica | |
Poland | GSK Investigational Site | Wroclaw |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Poland,
Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Pediatr Infect Dis J. 2013 Jul;32(7):777-85. doi: 10.1097/INF.0b013e31828d6b20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) | A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (=) 0.15 micrograms per milliliter (µg/mL). | At Month 1, post-booster dose | |
Primary | Number of Seroprotected Subjects Against Neisseria Meningitidis Serogroup C Using Baby Rabbit Completent (rSBA-MenC) | A seroprotected subject was defined as a subject with anti-rSBA-MenC titers greater than or equal to (=) 1:8. | At Month 1, post-booster dose | |
Secondary | Number of Seropositive Subjects for Anti-PRP | A seropositive subject was defined as a subject with anti-PRP antibody concentrations = 0.15 µg/mL. | At Month 0, before the booster dose | |
Secondary | Number of Subjects With Anti-PRP Antibody Concentrations = the Cut-off | The cut-off value of the assay was an anti-PRP antibody concentration = 1 µg/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-PRP Antibody Concentrations | Concentrations were expressed as geometric mean concentrations (GMCs) for the cut-off value of = 0.15 µg/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Seroprotected Subjects Against rSBA-MenC | A seroprotected subject was defined as a subject with anti-rSBA-MenC antibody titers = 1:8. | At Month 0, before the booster dose | |
Secondary | Number of Seropositive Subjects for Anti-rSBA-MenC | A seropositive subject for anti-rSBA-MenC was defined as a subject with antibody titers greater than or equal to (=) 1:128. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-rSBA-MenC Antibody Titres | Antibody titers were expressed as geometric mean titers (GMTs) for the seroprotection cut-off value of = 1:8. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Subjects With Polysaccharide N. Meningitidis Serogroup C (PSC) Antibody Concentrations = Cut-off Values | The cut-off values assessed were = 0.3 µg/mL and = 2 µg/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-PSC Antibody Concentrations | Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value of = 0.3 µg/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Seropositive Subjects for Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) | A seropositive subject was defined as a subject with anti-D and anti-T antibody concentrations = 0.1 international units per milliliter (IU/mL). | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-D and Anti-T Antibody Concentrations | Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value of = 0.1 IU/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations = Cut-off Values | The cut-off values assessed were 3.3 milli-international units per milliliter (mIU/mL), 10 mIU/mL and 100 mIU/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-HBs Antibody Concentrations | Concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL. | At Month 0 and Month 1, before and after booster dose | |
Secondary | Number of Seropositive Subjects for Anti-poliovirus Types 1, 2 and 3 | A seropositive subject was defined as a subject with anti-polio type 1, 2 or 3 = 1:8. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-poliovirus Types 1, 2 and 3 Antibody Titres | Titers were expressed as geometric mean titters (GMTs) for the seropositivity cut-off value of = 1:8. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) | A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations = 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations | Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off value = 5 EL.U/mL. | At Month 0 and Month 1, before and one month after booster dose | |
Secondary | Number of Subjects With Any Solicited Local Symptoms | Solicited local symptoms assessed included pain, redness and swelling. Any= all reports of the speecified symptom irrespective of intensity grade. | During the 8-day (Days 0-7) post-booster period | |
Secondary | Number of Subjects With Any Solicited General Symptoms | Solicited general symptoms assessed included drowsiness, irritability, loss of appetite and fever (defined as axillary temperature = 37.5º C). Any= all reports of the specified symptom irrespective of intensity grade and relationship to vaccination. | During the 8-day (Days 0-7) post-booster period | |
Secondary | Number of Subjects With Unsolicited Adverse Events (AEs) | An unsolicited AE was any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. | During the 31-day (Days 0-30) post-booster period | |
Secondary | Number of Subjects With Serious Adverse Events (SAEs) | SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. | After the booster dose of the study vaccine up to the study end (from Month 0 to Month 1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01182311 -
Duration of Long-term Immunity After Hepatitis B Virus Immunization
|
||
Completed |
NCT04971928 -
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
|
Phase 1 | |
Completed |
NCT03285620 -
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
|
Phase 1 | |
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05404919 -
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
|
Phase 2 | |
Completed |
NCT02153320 -
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Completed |
NCT03567382 -
Arresting Vertical Transmission of Hepatitis B Virus
|
Phase 4 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Not yet recruiting |
NCT03604016 -
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Completed |
NCT02540538 -
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
|
Phase 1 | |
Terminated |
NCT02604199 -
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Completed |
NCT02169674 -
Hepatitis B Booster Study in Adolescence
|
Phase 4 | |
Completed |
NCT02421666 -
A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV
|
N/A | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01368497 -
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 3 | |
Completed |
NCT01732354 -
Study for Consolidation Period of Chronic Hepatitis B
|
||
Recruiting |
NCT01462981 -
Cohort of Hepatitis B Research of Amsterdam
|
N/A |